TITLE:
Telavancin in Experimental Murine Pneumococcal Pneumonia
AUTHORS:
Suzannah M. Schmidt, Melissa J. Karau, Jayawant N. Mandrekar, James M. Steckelberg, Robin Patel
KEYWORDS:
Telavancin; Murine; Pneumonia
JOURNAL NAME:
Journal of Immune Based Therapies, Vaccines and Antimicrobials,
Vol.1 No.2,
July
23,
2012
ABSTRACT: We determined whether telavancin is as active in experimental immunocompetent murine pneumococcal pneumonia as is vancomycin or ceftriaxone. Experimental murine pneumonia was established by intratracheal administration of Streptococcus pneumoniae. Four groups of animals were studied, untreated and treated with vancomycin (110 mg/kg, bid, SQ), telavancin (40 mg/kg, bid, SQ), or ceftriaxone (50 mg/kg, bid, SQ) for 2 days. The untreated animals had a mean of 6.54 ± 0.82 log10 cfu/g lung. The vancomycin-, telavancin-, and ceftriaxone-treated animals had means of 2.01 ± 0.02, 2.00 ± 0.00, and 2.00 ± 0.01 log10 cfu/g lung, respectively (p-values